EYP-1901

DRUG10 trials

Conditions

DMEDiabetic Macular EdemaDiabetic Macular Edema (DME)Nonproliferative Diabetic RetinopathyWet Age Related Macular DegenerationWet Age-related Macular DegenerationWet age-related macular degeneration (wAMD)wAMD

Phase 1

First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

CompletedNCT04747197

EyePoint Pharmaceuticals, Inc.Wet Age-related Macular Degeneration

Start: 2021-01-20End: 2022-05-11Updated: 2023-07-19

Phase 2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

CompletedNCT05381948

EyePoint Pharmaceuticals, Inc.Wet Age-related Macular Degeneration

Start: 2022-06-30End: 2024-04-24Updated: 2025-10-15

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

CompletedNCT05383209

EyePoint Pharmaceuticals, Inc.Nonproliferative Diabetic Retinopathy

Start: 2022-09-28End: 2024-05-06Updated: 2025-08-15

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

CompletedNCT06099184

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema

Start: 2024-01-15End: 2024-10-24Updated: 2025-03-04

Phase 3

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Active, not recruitingNCT06668064

EyePoint Pharmaceuticals, Inc.wAMD, Wet Age Related Macular Degeneration

Start: 2024-10-22End: 2027-08-01Target: 400Updated: 2026-04-02

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Active, not recruitingNCT06683742

EyePoint Pharmaceuticals, Inc.wAMD, Wet Age Related Macular Degeneration

Start: 2024-11-27End: 2027-10-01Target: 400Updated: 2026-04-02

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD (EYP-1901-302)

Active, not recruitingCTIS2024-518030-83-00

Eyepoint Pharmaceuticals Inc.Wet age-related macular degeneration (wAMD)

Start: 2025-06-05Target: 143Updated: 2025-05-25

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

RecruitingNCT07449936

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema, Diabetic Macular Edema (DME), DME

Start: 2026-02-26End: 2028-08-01Target: 240Updated: 2026-03-16

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

RecruitingNCT07449923

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema, Diabetic Macular Edema (DME), DME

Start: 2026-02-09End: 2028-08-01Target: 240Updated: 2026-03-04

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants with Diabetic Macular Edema (DME) (EYP-1901-304)

Not yet recruitingCTIS2025-523938-10-00

Eyepoint Pharmaceuticals Inc.Diabetic Macular Edema (DME)

Target: 40Updated: 2026-03-30

Related Papers

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy — Methods & Clinical Development2025-02-105 citations

Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration.